Physician profile

Rafael D Hasbun

Internal Medicine · Marlton, NJ

NPI 1477533545

$334.75

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$210.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $199.71 2022-2024 Ozempic, Rybelsus, Wegovy
Abbvie INC. $33.41 2021-2024
Abbott Laboratories $24.56 2019
Eisai INC. $17.65 2020
Lilly USA, LLC $17.52 2024 Mounjaro
Pfizer INC. $16.88 2023
Glaxosmithkline, LLC. $13.67 2019
Sanofi Pasteur INC. $11.35 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Rafael D Hasbun

$334.75

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/248607/rafael-d-hasbun

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.